162 related articles for article (PubMed ID: 32803354)
21. Cutaneous leukocytoclastic vasculitis in dermatomyositis suggests malignancy.
Hunger RE; Dürr C; Brand CU
Dermatology; 2001; 202(2):123-6. PubMed ID: 11306833
[TBL] [Abstract][Full Text] [Related]
22. Association of antinuclear antibody status with clinical features and malignancy risk in adult-onset dermatomyositis.
Hoesly PM; Sluzevich JC; Jambusaria-Pahlajani A; Lesser ER; Heckman MG; Abril A
J Am Acad Dermatol; 2019 May; 80(5):1364-1370. PubMed ID: 30458207
[TBL] [Abstract][Full Text] [Related]
23. Dermatomyositis associated with malignancy. 12 case reports.
Dourmishev LA
Adv Exp Med Biol; 1999; 455():193-9. PubMed ID: 10599343
[TBL] [Abstract][Full Text] [Related]
24. Muscle biopsy findings predictive of malignancy in rare infiltrative dermatomyositis.
Uchino M; Yamashita S; Uchino K; Mori A; Hara A; Suga T; Hirahara T; Koide T; Kimura E; Yamashita T; Ueda A; Kurisaki R; Suzuki J; Honda S; Maeda Y; Hirano T; Ando Y
Clin Neurol Neurosurg; 2013 May; 115(5):603-6. PubMed ID: 22920633
[TBL] [Abstract][Full Text] [Related]
25. Clinical characteristics and prognostic analysis of Chinese dermatomyositis patients with malignancies.
Shao C; Li S; Sun Y; Zhang Y; Xu K; Zhang X; Huang H
Medicine (Baltimore); 2020 Aug; 99(34):e21899. PubMed ID: 32846853
[TBL] [Abstract][Full Text] [Related]
26. Clinical characteristics and prognosis of polymyositis and dermatomyositis associated with malignancy: a 25-year retrospective study.
Motomura K; Yamashita H; Yamada S; Takahashi Y; Kaneko H
Rheumatol Int; 2019 Oct; 39(10):1733-1739. PubMed ID: 31444556
[TBL] [Abstract][Full Text] [Related]
27. Hematological malignancy associated with polymyositis and dermatomyositis.
Marie I; Guillevin L; Menard JF; Hatron PY; Cherin P; Amoura Z; Cacoub P; Bachelez H; Buzyn A; Le Roux G; Ziza JM; Brice P; Munck JN; Sarrot-Reynauld F; Piette JC; Larroche C
Autoimmun Rev; 2012 Jul; 11(9):615-20. PubMed ID: 22079677
[TBL] [Abstract][Full Text] [Related]
28. Routine vs extensive malignancy search for adult dermatomyositis and polymyositis: a study of 40 patients.
Sparsa A; Liozon E; Herrmann F; Ly K; Lebrun V; Soria P; Loustaud-Ratti V; Bouyssou-Gauthier ML; Boulinguez S; Bédane C; Jauberteau MO; Vidal E; Bonnetblanc JM
Arch Dermatol; 2002 Jul; 138(7):885-90. PubMed ID: 12071815
[TBL] [Abstract][Full Text] [Related]
29. Malignancy associated with dermatomyositis - a retrospective single-center study with 33 patients.
Travassos AR; Borges-Costa J; Filipe P; Marques MS
Acta Reumatol Port; 2013; 38(2):92-7. PubMed ID: 24141345
[TBL] [Abstract][Full Text] [Related]
30. Malignancy in dermatomyositis: A retrospective paired case-control study of 202 patients from Central China.
Chang L; Zhang L; Jia H; Nie Z; Zhang L
Medicine (Baltimore); 2020 Aug; 99(34):e21733. PubMed ID: 32846794
[TBL] [Abstract][Full Text] [Related]
31. Characteristics of Patients Hospitalized for Cutaneous Squamous Cell Carcinoma.
Tripathi R; Knusel KD; Ezaldein HH; Bordeaux JS; Scott JF
Dermatol Surg; 2020 Jun; 46(6):742-746. PubMed ID: 31490307
[TBL] [Abstract][Full Text] [Related]
32. Malignant otitis externa hospitalizations: Analysis of patient characteristics.
Sylvester MJ; Sanghvi S; Patel VM; Eloy JA; Ying YM
Laryngoscope; 2017 Oct; 127(10):2328-2336. PubMed ID: 27882553
[TBL] [Abstract][Full Text] [Related]
33. Incidence and predictive factors for malignancies in 136 Japanese patients with dermatomyositis, polymyositis and clinically amyopathic dermatomyositis.
Azuma K; Yamada H; Ohkubo M; Yamasaki Y; Yamasaki M; Mizushima M; Ozaki S
Mod Rheumatol; 2011 Apr; 21(2):178-83. PubMed ID: 20922453
[TBL] [Abstract][Full Text] [Related]
34. Clinically amyopathic dermatomyositis: clinical features, response to medications and malignancy-associated risk factors in a specific tertiary-care-centre cohort.
Galimberti F; Li Y; Fernandez AP
Br J Dermatol; 2016 Jan; 174(1):158-64. PubMed ID: 26490490
[TBL] [Abstract][Full Text] [Related]
35. Mortality of Chinese patients with polymyositis and dermatomyositis.
Yang X; Hao Y; Zhang X; Geng Y; Ji L; Li G; Zhang Z
Clin Rheumatol; 2020 May; 39(5):1569-1579. PubMed ID: 31902027
[TBL] [Abstract][Full Text] [Related]
36. Incidence of dermatomyositis and clinically amyopathic dermatomyositis: a population-based study in Olmsted County, Minnesota.
Bendewald MJ; Wetter DA; Li X; Davis MD
Arch Dermatol; 2010 Jan; 146(1):26-30. PubMed ID: 20083689
[TBL] [Abstract][Full Text] [Related]
37. Trends and Outcomes of Venous Thromboembolism in Hospitalized Patients With Ovarian Cancer: Results From Nationwide Inpatient Sample Database 2003 to 2011.
Mittal V; Ahuja S; Vejella SS; Stempel JM; Palabindala V; Dourado CM; Leighton JC
Int J Gynecol Cancer; 2018 Oct; 28(8):1478-1484. PubMed ID: 30045139
[TBL] [Abstract][Full Text] [Related]
38. Association of Anti-Transcription Intermediary Factor 1γ Antibodies With Paraneoplastic Rheumatic Syndromes Other Than Dermatomyositis.
Venalis P; Selickaja S; Lundberg K; Rugiene R; Lundberg IE
Arthritis Care Res (Hoboken); 2018 Apr; 70(4):648-651. PubMed ID: 28704599
[TBL] [Abstract][Full Text] [Related]
39. Malignancy in dermatomyositis: A retrospective study of 201 patients seen at the University of Pennsylvania.
Bowerman K; Pearson DR; Okawa J; Werth VP
J Am Acad Dermatol; 2020 Jul; 83(1):117-122. PubMed ID: 32135206
[TBL] [Abstract][Full Text] [Related]
40. Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ.
Fiorentino DF; Chung LS; Christopher-Stine L; Zaba L; Li S; Mammen AL; Rosen A; Casciola-Rosen L
Arthritis Rheum; 2013 Nov; 65(11):2954-62. PubMed ID: 24037894
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
